ESTRO 2024 - Abstract Book

S2140

Clinical - Upper GI

ESTRO 2024

1 Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Chengdu, China. 2 Shandong Cancer Hospital and Institute, Department of Radiation Oncology, Jinan, China. 3 Anyang Cancer Hospital, The Fourth Affiliated Hospital of Henan University of Science and Technology, Department 6 of Radiotherapy, Anyang, China. 4 Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Department of Radiation Oncology, Tianjin, China. 5 The Fourth Hospital of Hebei Medical University, Department of Radiotherapy, Shijiazhuang, China. 6 Shandong Provincial Hospital Affiliated to Shandong First Medical University, Tumor Research and Therapy Center, Jinan, China. 7 Qilu Hospital of Shandong University, Department of Radiation Oncology, Jinan, China. 8 Affiliated Hospital of Jining Medical University, Department of Radiation Oncology, Jining, China. 9 Binzhou Medical University Hospital, Department of Radiation Oncology, Binzhou, China. 10 Yantai Yuhuangding Hospital, Department of Radiation Oncology, Yantai, China. 11 Jining First People’s Hospital, Department of Radiation Oncology, Jining, China. 12 Central Hospital Affiliated to Shandong First Medical University, Department of Radiation Oncology, Jinan, China. 13 Xijing Hospital, Air Force Medical University, Department of Radiation Oncology, Xi’an, China. 14 Weifang People’s Hospital, Department of Radiation Oncology, Weifang, China. 15 Hunan Cancer Hospital, the Affiliate Hospital of Xiangya Medical School, Central South University, Key Laboratory of Translational Radiation Oncology, Changsha, China. 16 University of Texas MD Anderson Cancer Center, Department of Thoracic Radiation Oncology, Houston, USA Small cell esophageal carcinoma (SCEC) is one of the deadliest neuroendocrine malignancies, which accounts for 0.4% to 2.8% of all esophageal cancers and often occurs in the middle and lower esophagus 1-4 . Due to the feature of rapid progression and high metastasis propensity, the prognosis is dismal, with a 5-year survival of ~10% for limited stage and practically zero for extensive stage 5-8 . Due to its rarity, it is not feasible to perform prospective randomized controlled trials (RCTs) on SCEC. No consensus on standardized treatment for SCEC has been reached at present. Currently, the vast majority of patients with limited-stage SCECs (LS-SCECs) are treated with definitive radiotherapy (RT) in Europe and U.S. 3,4,6,9-11 . The significant predisposition of RT in Western countries makes the direct comparison of RT and surgery difficult to perform by using local cancer registry system, such as The Surveillance, Epidemiology, and End Results (SEER) database. The purpose of this multicenter, retrospective study (ChiSCER) was to investigate the most optimal local treatment, outcomes, and risk factors impacting on survival endpoints in patients with LS-SCEC. Purpose/Objective:

Material/Methods:

Consecutive patients with LS-SCEC from 14 institutions between 2000 to 2020 in China were enrolled. Survival curves were constructed using the Kaplan-Meier method and compared by log-rank test. Univariate and multivariate Cox regression models and propensity score matching (PSM) analysis were adopted in prognostic analysis. Results were reported as hazard ratio (HR), 95% confidence interval (CI), and P value. Statistical significance was set as P value < 0.05 in a two-tailed test.

Results: